The Use and Misuse of Positron Emission Tomography in Lung Cancer Evaluation

Clinics in Chest Medicine

Volumn 32, Issue 4, 2011, Pages 749-762

  Chang, Ching Fei ^a   Rashtian, Afshin ^a   Gould, Michael K ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Mediastinum staging; Non small cell lung cancer; Positron emission tomography; Pulmonary nodules

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; MEDIASTINUM; MEDICAL LITERATURE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RADIATION FIELD; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARGET ORGAN; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC ERRORS; FLUORODEOXYGLUCOSE F18; HEALTH SERVICES MISUSE; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 80455177301     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.08.012     Document Type: Review

References (89)

1. van Tinteren H., Hoekstra O.S., Smit E.F., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002, 359(9315):1388-1392.
2. Verboom P., van Tinteren H., Hoekstra O.S., et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003, 30(11):1444-1449.
3. Ung Y.C., Maziak D.E., Vanderveen J.A., et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007, 99(23):1753-1767.
4. Ost D., Fein A.M., Feinsilver S.H. Clinical practice. The solitary pulmonary nodule. N Engl J Med 2003, 348(25):2535-2542.
5. Detterbeck F.C. Seeking a home for a PET, part 1: defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004, 125(6):2294-2299.
6. Wahidi M.M., Govert J.A., Goudar R.K., et al. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(Suppl 3):94S-107S.
7. Henschke C.I., McCauley D.I., Yankelevitz D.F., et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999, 354(9173):99-105.
8. Swensen S.J., Jett J.R., Sloan J.A., et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002, 165(4):508-513.
9. Gould M.K., Jett J.R., Sloan J.A., et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001, 285(7):914-924.
10. Cronin P., Dwamena B.A., Kelly A.M., et al. Solitary pulmonary nodules and masses: a meta-analysis of the diagnostic utility of alternative imaging tests. Eur Radiol 2008, 18(9):1840-1856.
11. Fletcher J.W., Kymes S.M., Gould M., et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008, 49(2):179-185. official publication, Society of Nuclear Medicine.
12. Marom E.M., Sarvis S., Herndon J.E., et al. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002, 223(2):453-459.
13. Barnett P.G., Ananth L., Gould M.K. Cost and outcomes of patients with solitary pulmonary nodules managed with PET scans. Chest 2010, 137(1):53-59.
14. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003, 126(6):1943-1951.
15. Gambhir S.S., Shepherd J.E., Shah B.D., et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998, 16(6):2113-2125. official journal of the American Society of Clinical Oncology.
16. Dietlein M., Weber K., Gandjour A., et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000, 27(10):1441-1456.
17. Gould M.K., Sanders G.D., Barnett P.G., et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 2003, 138(9):724-735.
18. Swensen S.J., Silverstein M.D., Ilstrup D.M., et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997, 157(8):849-855.
19. Croswell J.M., Baker S.G., Marcus P.M., et al. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010, 152(8):505-512. W176-80.
20. Ashraf H., Dirksen A., Loft A., et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011, 66(4):315-319.
21. Silvestri G.A., Gould M.K., Margolis M.L., et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007, 132(Suppl 3):178S-201S.
22. Toloza E.M. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003, 123(90010):137S-146S.
23. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003, 139(11):879-892.
24. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343(4):254-261.
25. Miller Y.E. Staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343(21):1571-1572. [author reply: 1572-3].
26. Detterbeck F.C. Seeking a home for a PET, Part 2: defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004, 125(6):2300-2308.
27. Verhagen A.F., Bootsma G.P., Tjan-Heijnen V.C., et al. FDG-PET in staging lung cancer: how does it change the algorithm?. Lung Cancer 2004, 44(2):175-181.
28. Cerfolio R.J., Bryant A.S. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg 2006, 81(6):1969-1973. [discussion: 1973].
29. Cerfolio R.J., Bryant A.S., Ojha B., et al. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 2005, 80(4):1207-1213. [discussion: 1213-4].
30. Nomori H., Watanabe K., Ohtsuka T., et al. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg 2004, 127(4):1087-1092.
31. Bille A., Pelosi E., Skanjeti A., et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009, 36(3):440-445. official journal of the European Association for Cardio-thoracic Surgery.
32. Kalff V., Hicks R.J., MacManus M.P., et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001, 19(1):111-118. official journal of the American Society of Clinical Oncology.
33. Hicks R.J., Kalff V., MacManus M.P., et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001, 42(11):1596-1604. official publication, Society of Nuclear Medicine.
34. Fischer B., Lassen U., Mortensen J., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361(1):32-39.
35. Maziak D.E., Darling G.E., Inculet R.I., et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009, 151(4):221-228. W-48.
36. Viney R.C., Boyer M.J., King M.T., et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004, 22(12):2357-2362. official journal of the American Society of Clinical Oncology.
37. Herder G.J., Kramer H., Hoekstra O.S., et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006, 24(12):1800-1806. official journal of the American Society of Clinical Oncology.
38. Gambhir S.S., Hoh C.K., Phelps M.E., et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996, 37(9):1428-1436. official publication, Society of Nuclear Medicine.
39. Scott W.J., Shepherd J., Gambhir S.S. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998, 66(6):1876-1883. [discussion: 1883-5].
40. Yap K.K., Yap K.S., Byrne A.J., et al. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2005, 32(9):1033-1040.
41. Harewood G.C., Wiersema M.J., Edell E.S., et al. Cost-minimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy. Mayo Clin Proc 2002, 77(2):155-164. Mayo Clinic.
42. Dunagan D., Chin R., McCain T., et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest 2001, 119(2):333-339.
43. Paesmans M., Berghmans T., Dusart M., et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010, 5(5):612-619. official publication of the International Association for the Study of Lung Cancer.
44. Nair V.S., Krupitskaya Y., Gould M.K. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009, 4(12):1473-1479. official publication of the International Association for the Study of Lung Cancer.
45. Nair V.S., Barnett P.G., Ananth L., et al. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest 2010, 137(5):1150-1156.
46. de Geus-Oei L.F., van der Heijden H.F., Corstens F.H., et al. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007, 110(8):1654-1664.
47. Vansteenkiste J., Fischer B.M., Dooms C., et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004, 5(9):531-540.
48. Lee D.H., Kim S.K., Lee H.Y., et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 2009, 4(7):816-821. official publication of the International Association for the Study of Lung Cancer.
49. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21(14):2651-2657. official journal of the American Society of Clinical Oncology.
50. Mac Manus M.P. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003, 21(7):1285-1292.
51. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005, 49(1):95-108.
52. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(33):8362-8370. official journal of the American Society of Clinical Oncology.
53. Cerfolio R.J., Bryant A.S., Winokur T.S., et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004, 78(6):1903-1909. [discussion: 1909].
54. Tanvetyanon T., Eikman E.A., Sommers E., et al. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008, 26(28):4610-4616. official journal of the American Society of Clinical Oncology.
55. Pottgen C., Levegrün S., Theegarten D., et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006, 12(1):97-106. an official journal of the American Association for Cancer Research.
56. Cerfolio R.J., Bryant A.S. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?. Ann Thorac Surg 2007, 84(4):1092-1097.
57. Cerfolio R.J., Bryant A.S., Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006, 131(6):1229-1235.
58. Port J. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004, 77(1):254-259.
59. Xu X., Yu J., Sun X., et al. The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer. Am J Clin Oncol 2008, 31(5):470-475.
60. de Langen A.J., van den Boogaart V., Lubberink M., et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 2011, 52(1):48-55. official publication, Society of Nuclear Medicine.
61. Pisters K.M., Kris M.G., Gralla R.J., et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993, 11(9):1757-1762. official journal of the American Society of Clinical Oncology.
62. Albain K.S., Swann R.S., Rusch V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374(9687):379-386.
63. Paul S., Mirza F., Port J.L., et al. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg 2011, 141(1):48-58.
64. Rebollo-Aguirre A.C., Ramos-Font C., Villegas Portero R., et al. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? evidence with systematic review of the literature. J Surg Oncol 2010, 101(6):486-494.
65. de Cabanyes Candela S., Detterbeck F.C. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010, 5(3):389-398. official publication of the International Association for the Study of Lung Cancer.
66. Cerfolio R.J., Ojha B., Mukherjee S., et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003, 125(4):938-944.
67. Hellwig D., Gröschel A., Graeter T.P., et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006, 33(1):13-21.
68. Hicks R.J., Kalff V., MacManus M.P., et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001, 42(11):1605-1613. official publication, Society of Nuclear Medicine.
69. De Ruysscher D., Kirsch C.M. PET scans in radiotherapy planning of lung cancer. Radiother Oncol 2010, 96(3):335-338. journal of the European Society for Therapeutic Radiology and Oncology.
70. Mac Manus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001, 92(4):886-895.
71. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005, 62(4):988-994.
72. Erdi Y.E., Rosenzweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002, 62(1):51-60. journal of the European Society for Therapeutic Radiology and Oncology.
73. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000, 55(3):317-324. journal of the European Society for Therapeutic Radiology and Oncology.
74. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999, 44(3):593-597.
75. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59(1):78-86.
76. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005, 63(4):1016-1023.
77. Feng M., Kong F.M., Gross M., et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 2009, 73(4):1228-1234.
78. Gillham C., Zips D., Pönisch F., et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol 2008, 88(3):335-341. journal of the European Society for Therapeutic Radiology and Oncology.
79. Roberts P.F., Follette D.M., von Haag D., et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000, 70(4):1154-1159. [discussion: 1159-60].
80. Graeter T.P., Hellwig D., Hoffmann K., et al. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003, 75(1):231-235. [discussion: 235-6].
81. Annema J.T., Hoekstra O.S., Smit E.F., et al. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. Lung Cancer 2004, 44(1):53-60.
82. Wallace M.B., Pascual J.M., Raimondo M., et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008, 299(5):540-546. the journal of the American Medical Association.
83. Wallace M., Pascual J.M., Raimondo M., et al. Complete " medical mediastinoscopy" under conscious sedation: a prospective blinded comparison of endoscopic and endobronchial ultrasound to bronchoscopic fine needle aspiration for malignant mediastinal lymph nodes. Gastrointest Endosc 2006, 63:AB96. [abstract].
84. Bryant A.S., Cerfolio R.J., Klemm K.M., et al. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 2006, 82(2):417-422. [discussion: 422-3].
85. Cerfolio R.J., Ojha B., Bryant A.S., et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004, 78(3):1017-1023. [discussion: 1017-23].
86. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348(25):2500-2507.
87. Kim S.K., Allen-Auerbach M., Goldin J., et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007, 48(2):214-220. official publication, Society of Nuclear Medicine.
88. Demura Y., Tsuchida T., Ishizaki T., et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003, 44(4):540-548. official publication, Society of Nuclear Medicine.
89. Uesaka D., Demura Y., Ishizaki T., et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med 2008, 49(10):1606-1612. official publication, Society of Nuclear Medicine.